GLP-1s and Pregnancy, Fertility & Birth Control: What Every Woman on Semaglutide or Tirzepatide Should Know

The short answer: GLP-1 medications like semaglutide and tirzepatide are not fertility treatments, but for some women they can make pregnancy more likely than expected — by restoring ovulation as weight comes down. Tirzepatide can also lower how well oral birth control is absorbed, while semaglutide generally does not. And because these medications are not considered safe in pregnancy, physicians advise stopping them well before trying to conceive. If you could become pregnant, this is a conversation to have with your prescriber early — not after a surprise.

If you are taking a GLP-1 medication for weight management, most of the information you have probably read focuses on appetite, side effects, and the number on the scale. One area gets far less attention than it deserves: what these medications mean for fertility, contraception, and pregnancy planning. For women of reproductive age, this is one of the most important conversations to have — and one of the least discussed.

This guide walks through what the current evidence shows, where the real risks are, and the questions worth raising with your care team. None of it is a substitute for individual medical advice; it is meant to help you ask better questions and make informed decisions alongside your physician.

Why unexpected pregnancies happen on GLP-1s

You may have seen stories about unexpected pregnancies among women taking GLP-1 medications — a pattern that has drawn considerable media attention. The mechanism is real, and it is not mysterious. GLP-1 medications are not acting directly on the ovaries to trigger ovulation. Instead, they work indirectly: as body weight drops and insulin sensitivity improves, the hormonal signaling that governs the menstrual cycle can normalize, and ovulation that had been irregular or absent can return.

This effect is most pronounced in women whose fertility was being suppressed by weight or by insulin resistance in the first place. Polycystic ovary syndrome (PCOS) is the clearest example. Because PCOS is closely tied to insulin resistance and irregular or absent ovulation, women with PCOS may see the most noticeable change in their cycles. Reviews of the clinical literature have found that GLP-1 receptor agonists can improve fertility in women with obesity and PCOS, with meta-analyses reporting higher rates of spontaneous pregnancy.⁴

The practical takeaway is straightforward: if you have been relying on the assumption that you “can’t get pregnant easily,” that assumption may no longer hold once you have lost a meaningful amount of weight on a GLP-1. Contraception planning should keep pace with that change.

The birth control question: tirzepatide vs. semaglutide

This is the single most under-explained point in most patient conversations, so it is worth being precise.

GLP-1 medications slow gastric emptying — that is part of how they reduce appetite. Because food and oral medications leave the stomach more slowly, there was a reasonable concern that they might interfere with how well oral birth control pills are absorbed. The evidence has sorted this out by medication.

Tirzepatide

Tirzepatide — a dual GLP-1/GIP receptor agonist — has been shown to reduce the absorption of oral contraceptives. A pharmacokinetic study found roughly a 20% decrease in overall oral-contraceptive exposure after a single 5 mg dose of tirzepatide.¹ Because of this, the prescribing information for tirzepatide advises women using oral contraception to add a barrier method (such as condoms), or switch to a non-oral method, for four weeks after starting the medication and for four weeks after each dose increase.²

Semaglutide

Semaglutide is different. Studies have not shown that it meaningfully reduces the bioavailability of oral contraceptives, and the same is true for some other agents in the class such as liraglutide and dulaglutide.¹ That does not mean the topic is irrelevant for semaglutide users. Nausea and vomiting — common, especially during dose increases — can cause you to lose a pill dose without realizing it, which can reduce real-world contraceptive reliability. For that practical reason, a backup method during episodes of GI upset is sensible regardless of which medication you take.

The bottom line: ask your prescriber which medication you are on and what that specifically means for your contraception. The answer is not the same for everyone, and “GLP-1s” as a category is too broad to be useful here.

Planning a pregnancy: why timing and washout matter

GLP-1 medications are not considered safe to use during pregnancy. Human data are still limited, and while early information has not flagged a clear increase in major birth defects, animal studies have raised developmental concerns — so the consistent guidance is to discontinue these medications before conception rather than wait and see.³

Because semaglutide and tirzepatide are long-acting and stay in the body for weeks, simply stopping the night before is not enough. Clinical guidance and the medications’ own labeling point to a washout period before trying to conceive. For shorter-acting agents this may be a few weeks; for semaglutide and tirzepatide, clinical guidance commonly cites a washout on the order of about eight weeks — roughly two months — before attempting to conceive.³⁵

If pregnancy is something you are thinking about in the next several months, that timeline is worth mapping out with your physician now. It also intersects with weight maintenance: stopping a GLP-1 has its own implications for keeping weight stable, which is a separate planning conversation your care team can help you navigate.

GLP-1s and PCOS: a more nuanced picture

For women with PCOS, GLP-1 medications sit at an interesting intersection. The same properties that aid weight loss — improved insulin sensitivity, reduced weight — can also help restore more regular menstrual cycles and, for some, improve the odds of conception.⁴ This can be genuinely positive for women who have struggled with both weight and fertility.

But it cuts both ways. A woman with PCOS who started a GLP-1 expecting it to help with weight, and who was not actively planning a pregnancy, may find her fertility has changed faster than her contraception strategy. This is exactly the population where the “unexpected pregnancy” stories tend to originate. The medication can be a useful tool in a PCOS care plan — but the fertility and contraception side of that plan should be deliberate, not incidental, and it should be directed by a clinician who knows your history.

What about men?

Most of the attention here is on women, but it is worth a brief note: in men, the metabolic improvements that come with significant weight loss may indirectly support reproductive parameters. The data are early and this is not a reason to start or stop a medication for that purpose — but it is part of the broader picture of how metabolic health and reproductive health are linked.³

The questions to bring to your physician

If you are on a GLP-1 — or considering one — and pregnancy is anywhere on your horizon, these are worth raising directly with whoever oversees your care:

• Which specific medication am I on, and does it affect how well my birth control works?
• Given my method of contraception, do I need a backup or a different method while on this medication?
• If I want to try to conceive, how far in advance should I stop, and what is the right washout window for me?
• If my cycles change or become more regular, what does that mean for my pregnancy risk?
• How will stopping the medication affect my weight, and what is the plan to maintain my progress?

These questions are worth raising at your next appointment rather than saving for after a surprise. Reproductive-health planning belongs in the conversation from the start.

Frequently asked questions

Can you get pregnant while taking a GLP-1 medication?

Yes. GLP-1 medications are not contraceptives. For some women — particularly those with PCOS or significant weight loss — fertility can actually improve while on the medication because ovulation becomes more regular. If you do not want to become pregnant, do not assume the medication offers any protection.

Does semaglutide make birth control less effective?

Studies have not shown that semaglutide meaningfully reduces the absorption of oral contraceptives. The more practical risk is that nausea or vomiting could cause a missed pill. Tirzepatide is the agent that has been shown to reduce oral-contraceptive absorption.¹

Do I need backup birth control on tirzepatide?

The prescribing information advises adding a barrier method, or switching to a non-oral method, for four weeks after starting tirzepatide and for four weeks after each dose increase, if you rely on oral contraception.² Confirm the specifics with your prescriber.

How long before pregnancy should I stop a GLP-1?

Clinical guidance commonly points to a washout of around two months — about eight weeks — for semaglutide and tirzepatide before attempting to conceive.³⁵ Your physician will tailor the timing to your medication and situation.

Are GLP-1s safe during pregnancy?

They are not recommended during pregnancy. Human data are limited and animal studies have raised developmental concerns, so the standard guidance is to stop before conceiving rather than continue.³

---

This article is for general educational purposes and is not medical advice. It does not establish a patient–provider relationship, and it should not be used to start, stop, or change any medication. Decisions about GLP-1 therapy, contraception, and pregnancy planning should be made with a licensed clinician who knows your individual health history. Compounded medications are not approved by the FDA.

References

1. Skelley JW, Swearengin K, York AL, Glover LH. The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception. J Am Pharm Assoc (2003). 2024;64(1):204–211.e4. doi:10.1016/j.japh.2023.10.037
2. Tirzepatide Prescribing Information. Eli Lilly and Company. DailyMed (U.S. National Library of Medicine).
3. Dilbaz B, et al. The effects of glucagon-like peptide-1 receptor agonists on fertility, contraception, and pregnancy: clinical perspectives. Eur J Contracept Reprod Health Care. 2026. doi:10.1080/13625187.2026.2644895
4. The dual impact of GLP-1 receptor agonists on metabolic and reproductive health in polycystic ovary syndrome: insights from human and animal trials. 2025. PMC12504844.
5. A systematic review on GLP-1 receptor agonists in reproductive health: integrating IVF data, ovarian physiology and molecular mechanisms. PMC12841515.